Radnostix, Inc. (INIS)
OTCMKTS · Delayed Price · Currency is USD
0.0350
-0.0001 (-0.28%)
At close: Nov 19, 2026
Radnostix Revenue
Radnostix had revenue of $2.57M in the quarter ending September 30, 2026, a decrease of -21.56%. This brings the company's total for the last twelve months to $10.52M, down -25.25% year-over-year. In the year 2025, Radnostix had annual revenue of $13.07M, down -5.97%. That makes Radnostix the 37,192nd largest company in the world by revenue and 4,867th in the United States.
Revenue (ttm)
10.52M
Revenue Growth
-25.25%
P/S Ratio
2.01
Revenue / Employee
233.78K
Employees
45
Market Cap
18.52M
Revenue by Segment
- Theranostics Products 6.84M 52.3%
- Calibration & Reference Products 4.25M 32.5%
- Cobalt Products 1.75M 13.4%
- Medical Device Products 228.95K 1.8%
Fiscal year ended Dec 31, 2025 See the full Radnostix breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.07M | -829.42K | -5.97% |
| Dec 31, 2024 | 13.90M | 1.63M | 13.31% |
| Dec 31, 2023 | 12.27M | 1.09M | 9.71% |
| Dec 31, 2022 | 11.18M | 1.52M | 15.73% |
| Dec 31, 2021 | 9.66M | 297.05K | 3.17% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sofgen Pharma | 373.80M |
| Eagle Pharmaceuticals | 257.55M |
| MariMed | 167.28M |
| Earth Science Tech | 34.21M |
| Healthy Extracts | 5.99M |
| Bio Essence | 3.03M |
| Panacea Life Sciences Holdings | 2.76M |
Radnostix News
- 4 days ago - Radnostix, Inc. Reports FY2026 3rd Quarter and Nine Months Results - Theranostics Sales Up 15% Year-over-Year, Signs Agreement to Sell Fluorine Products/DUF6 Assets to Nano Nuclear Energy, Submits Type II DMF for Sodium Iodide I-131 API - PRNewsWire
- 4 weeks ago - Radnostix and NANO Nuclear Energy Announce Joint Submission of Letter of Intent to NRC Seeking Consent for Transfer of License SUB-1011, Following Lea County Approval of Property LOI - PRNewsWire
- 7 weeks ago - Radnostix Signs Definitive Agreement to Divest DUF6 and Fluorine Assets to NANO Nuclear - PRNewsWire
- 3 months ago - Radnostix, Inc. Reports FY2026 2nd Quarter and Six Months Results - Completes Execution of FDA 483 & Recall Actions, Restores Capsule Inventory, Completes Lucerno Dynamics Asset Acquisition - PRNewsWire
- 4 months ago - Radnostix Acquires Lucerno Dynamics Assets Expanding Radiopharma Medical Device Portfolio - PRNewsWire
- 6 months ago - Radnostix, Inc. Reports FY2026 Q1 Results - Revenue Declines 27% Primarily Due to Voluntary Product Recalls, Isotope Supply Disruptions, and Planned Operational Shutdown - PRNewsWire
- 7 months ago - Radnostix, Inc. Reports FY2025 Results - Second-Highest Annual Revenue in Company History; Delivers Strong Growth in Calibration & Reference Products and Advances Key Product Launches in 2025 - PRNewsWire
- 8 months ago - Radnostix announces mutual termination of APA related to DUF6 assets - TheFly